Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2954-2959

  Sun, Xuefeng ^a   Chen, Yunshuang ^a   Xiao, Qing ^a   Wang, Yong ^a   Zhou, Jianhui ^a   Ma, Zhifang ^a   Xiang, Jing ^a   Chen, Xiangmei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

anticoagulation; argatroban; bleeding; intermittent veno venous hemofiltration

Indexed keywords

ARGATROBAN; D DIMER;

ACUTE KIDNEY FAILURE; ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; FEMALE; HEMOFILTRATION; HIGH RISK PATIENT; HUMAN; INTERMITTENT VENO VENOUS HEMOFILTRATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE COUNT; VENOUS BLOOD;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMOFILTRATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RISK FACTORS; SURVIVAL RATE;

EID: 80053196642     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq805     Document Type: Article

References (25)

1. Lins RL, Elseviers MM, Van der Niepen P et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transpl 2009; 24: 512-518
2. Fuiano G, Di Filippo S, Memoli B et al. Italian Society of Nephrology. Guidelines for dialysis. Replacement therapy for acute renal failure in critically ill patients. G Ital Nefrol 2004; 21 (Suppl 28): S1-S10
3. Guérin C, Girard R, Selli JM et al. Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: results from a multicenter prospective epidemiological survey. Intensive Care Med 2002; 28: 1411-1418
4. Amanzadeh J, Reilly RF Jr. Anticoagulation and continuous renal replacement therapy. Semin Dial 2006; 19: 311-316 (Pubitemid 44091706)
5. Bagshaw SM, Laupland KB, Boiteau PJ et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005; 20: 155-161 (Pubitemid 41219636)
6. Monchi M, Berghmans D, Ledoux D et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265 (Pubitemid 38253417)
7. Durão MS, Monte JC, Batista MC et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008; 36: 3024-3029
8. Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 2002; 32: 9-14 (Pubitemid 37449298)
9. Ikoma H. Development of argatroban as an anticoagulant and antithrombin agent in Japan. Pathophysiol Haemost Thromb 2002; 32: 23-28 (Pubitemid 37449300)
10. Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract 2008; 109: c80-c94
11. Link A, Girndt M, Selejan S et al. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009; 37: 105-110
12. Murray PT, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in endstage renal disease. Kidney Int 2004; 66: 2446-2453
13. Ota K, Akizawa T, Hirasawa Y et al. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003; 1: 1623-1630 (Pubitemid 36939638)
14. Dager WE. Dosing nomograms: silos on a slope. Ann Pharmacother 2009; 43: 114-1147
15. Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13: 41-47
16. Uchino S, Bellomo R, Morimatsu H et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007; 33: 1563-1570 (Pubitemid 47312485)
17. Garcés EO, Victorino JA, Veronese FV. Anticoagulation in continuous renal replacement therapies (CRRT). Rev Assoc Med Bras 2007; 53: 451-455
18. Kim YG. Anticoagulation during haemodialysis in patients at high-risk of bleeding. Nephrology (Carlton) 2003; 8 (Suppl): S23-S27
19. Morabito S, Guzzo I, Solazzo A et al. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003; 16: 566-571 (Pubitemid 38120467)
20. Burry LD, Tung DD, Hallett D et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother 2009; 43: 1419-1425
21. Tillman J. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy. Nurs Crit Care 2009; 14: 191-199
22. Uchino S, Fealy N, Baldwin I et al. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004; 50: 76-80 (Pubitemid 38064004)
23. Româo JE Jr., Fadil MA, Sabbaga E et al. Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency. Nephrol Dial Transplant 1997; 12: 106-110 (Pubitemid 27046211)
24. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329 (Pubitemid 30140749)
25. Swan SK, St Peter JV, Lambrecht LJ et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-770 (Pubitemid 30457355)